Beth Devine

Professor Emeritus, The CHOICE Institute. Adjunct Professor: Biomedical Informatics. Member: Institute for Public Health Genetics.

CHOICE Faculty, Department of Pharmacy, Institute for Innovative Pharmacy Practice, Pharmacy Faculty, Plein Center in Geriatrics Faculty, School Faculty

Telephone: (425) 891-8074


Office Location: H-375-D Box 357630 1959 NE Pacific St Seattle ,WA 98195-7630



  • Post-doctoral Fellowship, The CHOICE Institute, UW and Roche Global Pharma Business
  • PhD, Health Services Research, UW
  • MBA, University of San Francisco
  • PharmD, University of the Pacific
  • Clinical Pharmacy Residency, Palo Alto VA Medical Center

Research Interests

  • Evidence synthesis; systematic reviews, meta-analysis, network meta-analysis using Bayesian and frequentist methods;
  • Effectiveness of pharmacogenomic biomarker-guided medication use on clinical outcomes, using real world evidence in the context of electronic clinical data;
  • Health technology assessment and outcomes research; preference-based methods, discrete choice experiments and multi-criteria decision analysis.

Courses Taught

  • HEOR 531/HSERV 584 – Assessing Outcomes in Health & Medicine;
  • PHRMCY 514 – Design and Analysis of Medical Studies
  • HECON – Health Technology Assessment

Selected Publications

Manuscripts Submitted and under Review

  • Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Devine B. Medical and non-medical costs of sickle cell disease, treatments, and related complications: A Systematic Review and Landscape Analysis. (submitted to PharmacoEconomics, August 2021)
  • 2 Jiang S, Mathias, Hendrix N, Shirts B, Veenstra DL, Devine B. Customizing value-based methods to prioritize implementation of pharmacogenomic clinical decision support for Learning Health Systems: A cost-utility analysis. (submitted to Genetics in Medicine, September 2021)
  • Knerr S, Guo B, Mittendorf KF, Goddard KAB, Devine EB and the CHARM Study Team. Risk-reducing surgery in unaffected women receiving cancer genetic testing in an integrated healthcare system. (under review at J Clin Onc, July 2021)
  • Saldarriaga EM, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine, B. Assessing payers’ preferences for real world evidence: A discrete choice experiment. (under revision at Value Health, August 2021)
  • Quach D, Devine B, et al. Gene therapies for Sickle Cell Disease. A Systematic Review and Landscape Analysis. (under revision at Expert Rev Pharmacoecon Outcomes Res)
  • Chaitesipaseut L, Wilson-Norton J, Trivelli K, Mikes T, Devine B. Feasibility of conducting pharmacogenomic-guided medication
  • therapy management in retirement communities. (under revision at J Am Coll Clin Pharm, August 2021)

Peer-Reviewed Publications

  • Jiao B, Baldwin Z, Basu A, Roth J, Bender MA, Devine B. Estimates of the Cost-effectiveness of Screening and Treatments for Sickle Cell Disease: A Systematic Review and Landscape Analysis. (in press at PharmacoEconomics, Aguust 2021)
  • Jiao B, Baldwin Z, Basu A, Roth J, Bender MA, Devine B. Health State Utilities for Sickle Cell Disease: A Systematic Review and Landscape Analysis. (in press at Value Health, August 2021)
  • *Lee D, Kim Y, Devine B. Spillover effects of mental disorders on family members’ utility: SF-6D scores from a US sample. 2021 Aug 11:272989X211027146. doi: 10.1177/0272989X211027146. Online ahead of print. PMID: 34378438
  • *Hendrix N, Kim DD, Patel KS, Devine B. Differences in the selection of health state utility values by sponsorship in published cost-effectiveness analyses. Med Decis Making. 2021 Apr;41(3):366-372. doi: 10.1177/0272989X20985821. Epub 2021 Jan 15.
  • *Cha AS, Chen Y, Fazioli K, Rivara M, Devine, B. Microvascular benefits of new antidiabetic agents: A systematic review and network meta-analysis of renal outcomes. J Clin Endocrinol Metab. 2021 Mar 25;106(4):1225-1234. doi: 10.1210/clinem/dgaa894
  • *Wang WJ, Devine B, Basu A. Use of the convoluted Poisson process in systematic reviews. Res Synth Methods 2020 Nov 1.
  • doi: 10.1002/jrsm.1465. Online ahead of print.
  • Chen S, Yun S, Graf J, Beal B, Bansal A, Carlson J, Basu A, Devine B. The REAdi (Real-World Evidence Assessments and Needs Guidance) Tool: A Framework for Evaluating Real-World Evidence. J Manag Care Spec Pharm. 2021 Jan;27(1):95-104.
  • doi: 10.18553/jmcp.2021.27.1.095.
  • *Jiao B, Veenstra D, Lee W, Carlson J, Devine B. The use of real-world evidence in ICER’s scoping process and clinical evidence assessment. J Manag Care Spec Pharm. 2020 Dec;26(12):1590-1595. doi: 10.18553/jmcp.2020.26.12.1590.
  • *Dhippayom T, Rattanachaisit N, Jhunsom S, Dilokthornsakul P, Chaiyakunapruk N, Devine B. Comparative effects of telemedicine and face-to-face anticoagulation management: A systematic review and network meta-analysis. J Am Pharm Assoc (2003). Nov-Dec 2020;60(6):880-891.e9.doi: 10.1016/j.japh.2020.06.010. Epub 2020 Jul 21.
  • Dhippayom T, Devine B. Letter to the editor for a published article titled, “The effect of online versus hospital warfarin management on patient outcomes: A systematic review and meta-analysis. Int J Clin Pharm. April 2, 2020.